Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIKAYCE for Mycobacterium Xenopi Pulmonary Infection
NCT06585020Phase 2Recruiting
- Sponsor
- CHU Amiens-Picardie
- Start
- Oct 2024
- Primary completion
- Dec 2030
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised trial of amikacin liposome inhalation suspension in Mycobacterium xenopi infection, sponsored by CHU Amiens-Picardie. Started Oct 2024; status: recruiting.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Mycobacterium xenopi infection
Beyond the preview
Go deeper on NCT06585020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585020.